<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Enabling Evolutionary Therapy in Metastatic Cancer Lacking Serum Biomarkers - Health AI Hub</title>
    <meta name="description" content="This paper addresses the critical need for reliable tumor monitoring to enable evolutionary therapy (ET) in metastatic cancers, particularly those lacking serum">
    <link rel="icon" type="image/svg+xml" href="../favicon.svg">
    <link rel="icon" type="image/png" sizes="32x32" href="../favicon-32x32.png">
    <link rel="icon" type="image/png" sizes="16x16" href="../favicon-16x16.png">
    <link rel="stylesheet" href="../styles.css">
</head>
<body>
    <header>
        <div class="container">
            <div class="breadcrumb">
                <a href="../index.html">‚Üê Back to all papers</a>
                <a href="../index.html" class="home-btn">üè† Home</a>
            </div>
        </div>
    </header>

    <main class="container paper-detail">
        <article>
            <h1>Enabling Evolutionary Therapy in Metastatic Cancer Lacking Serum Biomarkers</h1>

            <div class="paper-metadata">
                <div class="meta-row">
                    <strong>arXiv ID:</strong> <a href="http://arxiv.org/abs/2512.19485v1" target="_blank">2512.19485v1</a>
                </div>
                <div class="meta-row">
                    <strong>Published:</strong> 2025-12-22
                </div>
                <div class="meta-row">
                    <strong>Authors:</strong> Eva Moln√°rov√°, Ties A. Mulders, Marcela Spee-Dropkov√°, Louise M. Spekking, Sepinoud Azimi, Irene Grossmann, Anne-Marie C. Dingemans, Kate≈ôina Sta≈àkov√°
                </div>
                <div class="meta-row">
                    <strong>Categories:</strong> q-bio.PE
                </div>
                <div class="meta-row">
                    <strong>Relevance Score:</strong> 0.98 / 1.00
                </div>
            </div>

            <div class="action-buttons">
                <a href="http://arxiv.org/abs/2512.19485v1" target="_blank" class="btn btn-primary">View on arXiv</a>
                <a href="https://arxiv.org/pdf/2512.19485v1" target="_blank" class="btn btn-primary">Download PDF</a>
            </div>

            <section class="paper-section">
                <h2>Summary</h2>
                <p class="summary-text">This paper addresses the critical need for reliable tumor monitoring to enable evolutionary therapy (ET) in metastatic cancers, particularly those lacking serum biomarkers like NSCLC. It demonstrates, using a virtual patient model, that current standard RECIST 1.1 criteria are inadequate, while 3D volumetric imaging accurately captures tumor burden and dynamics, which are essential for guiding ET.</p>
            </section>

            <section class="paper-section">
                <h2>Medical Relevance</h2>
                <p>This research is crucial for advancing personalized oncology by demonstrating how to overcome a major hurdle for evolutionary therapy in common metastatic cancers without biomarkers, potentially leading to more effective and adaptive patient-centered treatment strategies that control disease progression long-term.</p>
            </section>

            
            <section class="paper-section">
                <h2>AI Health Application</h2>
                <p>The paper suggests integrating 'automated segmentation' of tumors from medical images (e.g., radiographic imaging) to accurately capture tumor burden and dynamics. This is a direct application of AI (specifically computer vision and machine learning) in medical image analysis for disease monitoring, treatment response assessment, and guiding therapeutic decisions in cancer care.</p>
            </section>
            

            <section class="paper-section">
                <h2>Key Points</h2>
                <ul class="key-points">
                    
                    <li>Evolutionary therapy (ET) aims to control tumor evolution by adjusting treatment, requiring robust monitoring of tumor dynamics rather than eradication.</li>
                    
                    <li>While some cancers (e.g., mCRPC, relapsed platinum-sensitive ovarian cancer) use serum biomarkers for ET guidance, many (e.g., metastatic NSCLC) lack reliable biomarkers, relying instead on radiographic imaging.</li>
                    
                    <li>Current radiographic assessment using RECIST 1.1 is insufficient for ET because it uses 1D measurements of a few lesions, defines progression relative to nadir, can miss early regrowth, underrepresent tumor burden, and obscure disease trends.</li>
                    
                    <li>A virtual NSCLC patient model was used to compare different measurement methodologies.</li>
                    
                    <li>The study found that lesion selection and measurement dimensionality significantly impact progression detection, with 2D metrics offering only modest improvement over 1D.</li>
                    
                    <li>Only 3D volumetric measurements were shown to accurately capture both total tumor burden and its dynamic changes, which are crucial for informing mathematical models in ET.</li>
                    
                    <li>To enable ET in biomarker-lacking cancers, response assessment must evolve beyond RECIST, incorporating volumetric imaging, automated segmentation, potentially liquid biopsies, and new progression criteria.</li>
                    
                </ul>
            </section>

            <div class="two-column">
                <section class="paper-section">
                    <h2>Methodology</h2>
                    <p>The study utilized a virtual patient model of non-small cell lung cancer (NSCLC) to simulate and compare the efficacy of different tumor measurement approaches (1D, 2D, 3D volumetric) and lesion selection strategies in detecting tumor progression and accurately representing tumor burden and dynamics under various treatment scenarios.</p>
                </section>

                <section class="paper-section">
                    <h2>Key Findings</h2>
                    <p>The primary findings reveal that RECIST 1.1, with its 1D measurements and nadir-based progression criteria, is inadequate for guiding evolutionary therapy. While 2D measurements provide a slight improvement, only 3D volumetric measurements consistently and accurately capture the true tumor burden and its dynamic changes, which are essential inputs for ET mathematical models.</p>
                </section>
            </div>

            <section class="paper-section">
                <h2>Clinical Impact</h2>
                <p>The findings suggest a paradigm shift in radiographic response assessment is necessary for a significant portion of metastatic cancer patients. Implementing 3D volumetric imaging, coupled with automated segmentation and redefined progression criteria, would enable the clinical application of evolutionary therapy in cancers like NSCLC, offering an adaptive, patient-specific approach to manage and control disease progression more effectively.</p>
            </section>

            
            <section class="paper-section">
                <h2>Limitations</h2>
                <p>The study relies on a virtual NSCLC patient model, which provides a controlled environment for simulation but requires validation with real-world clinical data from patients to confirm its findings and applicability in diverse clinical settings.</p>
            </section>
            

            
            <section class="paper-section">
                <h2>Future Directions</h2>
                <p>Future efforts should focus on integrating volumetric imaging into routine clinical practice, developing automated segmentation techniques for accurate and efficient tumor measurement, exploring the synergistic potential of liquid biopsies, and establishing new, ET-specific progression criteria to facilitate the broad adoption of adaptive, patient-centered treatments.</p>
            </section>
            

            <section class="paper-section">
                <h2>Medical Domains</h2>
                <div class="tags">
                    
                    <span class="tag">Oncology</span>
                    
                    <span class="tag">Medical Imaging</span>
                    
                    <span class="tag">Computational Biology</span>
                    
                    <span class="tag">Personalized Medicine</span>
                    
                </div>
            </section>

            <section class="paper-section">
                <h2>Keywords</h2>
                <div class="tags">
                    
                    <span class="tag tag-keyword">Evolutionary Therapy</span>
                    
                    <span class="tag tag-keyword">Metastatic Cancer</span>
                    
                    <span class="tag tag-keyword">NSCLC</span>
                    
                    <span class="tag tag-keyword">Biomarkers</span>
                    
                    <span class="tag tag-keyword">RECIST</span>
                    
                    <span class="tag tag-keyword">Volumetric Imaging</span>
                    
                    <span class="tag tag-keyword">Tumor Dynamics</span>
                    
                    <span class="tag tag-keyword">Adaptive Therapy</span>
                    
                </div>
            </section>

            <section class="paper-section">
                <h2>Abstract</h2>
                <p class="abstract">Evolutionary therapy (ET) aims to steer tumor evolution by adjusting treatment timing and dosing to control rather than eradicate tumor burden. Clinical use requires reliable monitoring of tumor dynamics to inform mathematical models that guide therapy. In cancers such as metastatic castrate-resistant prostate cancer and relapsed platinum-sensitive ovarian cancer, ET models are informed by serial serum biomarkers. For cancers lacking reliable biomarkers, such as metastatic non-small cell lung cancer (NSCLC), radiographic imaging remains the primary method for treatment response assessment, typically using RECIST 1.1 criteria. RECIST, which tracks a few lesions with one-dimensional (1D) measurements and defines progression relative to the nadir, the smallest tumor burden recorded after treatment, was not designed to support ET. It may miss early regrowth, underrepresent tumor burden, and obscure disease trends. Using a virtual NSCLC patient model, we demonstrate that lesion selection and measurement dimensionality strongly affect progression detection. Two-dimensional metrics provide modest improvement, but only 3D volumetric measurements accurately capture both tumor burden and its dynamics, which are key requirements for ET. To support ET in cancers lacking biomarkers, response assessment must evolve beyond RECIST by integrating volumetric imaging, automated segmentation, and potentially liquid biopsies, alongside redefining progression criteria to enable adaptive, patient-centered treatments.</p>
            </section>

            
            <section class="paper-section">
                <h2>Comments</h2>
                <p>15 pages including references, 3 figures, 1 box</p>
            </section>
            

            
        </article>
    </main>

    <footer class="container">
        <p><a href="../index.html">‚Üê Back to all papers</a></p>
    </footer>
</body>
</html>